ClinicalTrials.gg
Active, not recruitingNCT06127238Updated Nov 5, 2026

Study of ST-1898 in Advanced Renal Cell Carcinoma

A Phase 1/2 interventional study of ST-1898 tablets in Advanced Renal Cell Carcinoma, sponsored by Beijing Scitech-Mq Pharmaceuticals Limited. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beijing Scitech-Mq Pharmaceuticals Limited · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2023, registered Oct 2023).
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Planned enrollment
75th of 190
90 · median 66
Started
2023
with 29 others
Phase 1/2
24 of 235
11 open now
Primary completion
2027-02
later than 72 of 141 live
Registered
121st of 235
by date

Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 75th largest by planned enrollment of the 190 interventional ones that give a count, is one of 30 that started in 2023, is one of 24 in phase 1/2, reaches primary completion later than 72 of the 141 other live ones, and was the 121st registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL,PDGFRA,RET,KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in patients with advanced renal cell carcinoma (RCC).

In phase Ib, the primary objectives are to assess the safety and tolerability, and to determine the maximum tolerated dose (MTD) of ST-1898 tablets in patients with advanced RCC. Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy in patients with advanced RCC.

In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in patients with advanced RCC. The secondary objective is to evaluate the safety of ST-1898 tablets in patients with advanced RCC.

03

Conditions studied

  • Advanced Renal Cell Carcinoma

Keywords

  • ST-1898, renal cell carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 18 years
  2. of three months or more
  3. Histologically and medical imaging confirmed unresectable, locally advanced or renal cell carcinoma. In Dose Escalation Phase, subjects should be progressed with standard therapy, not eligible for standard therapy or no standard therapy available;in Dose Expansion Phase, subjects should be progressed with prior and tyrosine kinase inhibitor therapy.
  4. With agreement to provide a tumor tissue specimen
  5. Has the ability to understand and willingness to sign a written ICF before the performance of any study-specific procedures on this protocol
  6. Has at least one as defined by version 1.1
  7. Has an (ECOG) performance status (PS) of 0-1
  8. Has adequate organ function defined as follows:

    1. Bone marrow : (ANC)≥1.5×10\^9 /L, level ≥ 90 g/L and count (PLT) ≥ 90 x10\^9/L, no transfusions and no use of colony stimulating factor within 2 weeks prior to routine blood test) at screening;
    2. Liver: transaminase levels (/ALT) ≤ 3.0× (ULN), AST/ALT ≤ 5×ULN for liver metastasis; total (TBILI) ≤ 1.5 ×ULN;
    3. Kidney: Creatinine ≤1.5×ULN
    4. Heart: ≥50%
    5. Coagulation function: ≤1.5×ULN,APTT≤1.5×ULN (except for the prophylactic use of anticoagulants)
    6. Urine protein ≤1+; or in the condition of urine protein ≥2+, quantitative measurement of the 24-hour urine protein is \< 1g
  9. Women of child bearing potential must have a negative serum pregnancy test within 7 days before first study drug administration. Female patients of child bearing potential, or a male patients with a female partner of (defined as all women physiologically capable of becoming pregnant), must agree to use a highly effective method of during screening, during the period of drug administration and for 120 days after stopping study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Has received another anti-tumor therapy within two weeks or within 5 half-life of anti- tumor drug prior to the first dose
  2. Has had major surgery within 4 weeks before the first study drug administration (except tumor , puncture, invasive dental procedures such as tooth extraction, dental implants etc.)
  3. Current or previous severe retinopathy who, in the judgment of the Investigator or specialist, are not suitable for enrollment
  4. Has had any history of major cardiovascular event within 6 months prior to study drug administration including but not limited to :

    1. Serious arrhythmia or cardiac conduct abnormality , such as degree II-III atrioventricular block or ventricular arrhythmia needs to be treated
    2. extension: male >450 ms, female >470 ms
    3. Acute coronary syndrome, stroke, deep vein thrombosis, pulmonary- thromboembolism, arterial thrombosis, congestive heart failure, aortic dissection etc.
    4. Class ≥ II
    5. Has uncontrolled hypertension, as defined by a sustained blood pressure (BP) > 140/90 mmHg with antihypertensive treatment
  5. Has with symptoms or with evidence of progression
  6. Has Interstitial lung disease or radiation pneumonia requiring treatment by
  7. Has other malignant tumors in the last 5 years (not including non-melanoma skin cancer, breast cancer or cervical cancer in situ, and Non-Muscle-invasive bladder cancer that have been cured)
  8. Has ≥ grade 3 hemorrhage/bleeding event within 6 months prior to study drug administration or currently ≥ grade 2 hemorrhage or event of high risk of hemorrhage) including active gastrointestinal ulcer or esophageal varices
  9. Concomitant medication with strong inducers of , strong inhibitors of CYP3A4, or CYP3A4 substrates with narrow therapeutic windows within 2 weeks prior to first dose.
  10. Has not recovered from toxicities caused by prior therapy to ≤ Grade 1 (except for peripheral neuropathy becoming ≤Grade 2, alopecia, and other events judged tolerable by the Investigator and without safety risks).
  11. Active (asymptomatic hepatitis B carriers with HBV DNA \< 2000 IU/mL are allowed to be enrolled), virus (HCV) antibody-positive and HCV-RNA- positive, or other active hepatitis, moderate-to-severe cirrhosis, are allowed to receive prophylactic antiviral therapy other than interferon.
  12. Has acute bacterial, viral or fungal infections, requiring systemic anti-infective treatment.
  13. positive
  14. Pregnant or lactating females
  15. Drug or alcohol dependents
  16. Has significant disorder of neurology or mental disease or poorly compliance
  17. Unable to swallow oral medications or condition or conditions that in the judgment of the Investigator which severely interfere with gastrointestinal absorption, such as dysphagia, intestinal obstruction, etc.
  18. Clinically uncontrollable third interstitial effusion that, in the judgment of the Investigator, is unsuitable for enrollment.
  19. Has a history of other serious systemic disease, or any other reason that might interfere with participation in trial or interfere with interpretation of trial results, in the judgement of the Investigator, that are not qualified to participate in this trial.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    ST-1898 Phase Ib

    Dose Escalation:participants will be administered orally at 100mg,140mg,160mg,180mg, 220mg,QD during the study, until disease progression or intolerable toxicity.

    Drug: ST-1898 tablets

  • Experimental
    ST-1898 Phase II

    Dose Expansion: participants with advanced renal cell carcinoma will be dministered orally at recommended phase II dose from phase Ib once daily during the study, until disease progression or intolerable toxicity.

    Drug: ST-1898 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ib Dose Escalation:Maximum Tolerated Dose (MTD)

    The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first cycle (21days) of treatment.

    Time frame: Within the first cycle (21days)

  2. Phase Ib Dose Escalation: The Number and frequency of treatment-related adverse events (AEs) and treatment-related serious adverse events (SAEs)

    The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.

    Time frame: Approximately 18 months

  3. Phase II Expansion: Objective Response Rate (ORR)

    ORR is defined as The percentage of participants who experience a CR or PR based on RECIST 1.1 (CR: Complete Response, Disappearance of all target lesions, PR: Partial Response, At least a 30% decrease in the sum of diameters of target lesions)

    Time frame: Approximately 18 months

Secondary outcomes

  1. Phase Ib Dose Escalation: Plasma PK

    To assess plasma pharmacokinetics (PK) of oral administration of ST-1898 in participants with advanced renal cell carcinoma

    Time frame: On Day 1, 8, 21 of Cycle 1 and Day 1 of Cycle 3, approximately 10 weeks

  2. Phase Ib Dose Escalation: ORR

    Objective Response Rate (ORR) per RECIST 1.1

    Time frame: Approximately 18 months

  3. Phase Ib Dose Escalation: DOR

    DOR Duration of Response (DOR) per RECIST 1.1

    Time frame: Approximately 18 months

  4. Phase Ib Dose Escalation: PFS

    Progression-Free Survival (PFS) per RECIST 1.1

    Time frame: Approximately 18 months

  5. Phase Ib Dose Escalation: DCR

    Disease Control Rate (DCR) per RECIST 1.1

    Time frame: Approximately 18 months

  6. Phase Ib Dose Escalation: OS

    Overall Survival (OS)

    Time frame: Approximately 30 months

  7. Phase Ib Dose Escalation: TTP

    Time to Progression(TTP)per RECIST 1.1

    Time frame: Approximately 18 months

  8. Phase II Dose Expansion: DOR

    DOR Duration of Response (DOR) per RECIST 1.1

    Time frame: Approximately 18 months

  9. Phase II Dose Expansion: PFS

    Progression-Free Survival (PFS) per RECIST 1.1

    Time frame: Approximately 18 months

  10. Phase II Dose Expansion: DCR

    Disease Control Rate (DCR) per RECIST 1.1

    Time frame: Approximately 18 months

  11. Phase II Dose Expansion: OS

    Overall Survival (OS) per RECIST 1.1

    Time frame: Approximately 30 months

  12. Phase II Dose Expansion: OS12m

    12-Month survival rate(OS12m)

    Time frame: 12 months

  13. Phase II Dose Expansion: The Number and frequency of treatment-related adverse events and serious adverse events (SAEs)

    The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.

    Time frame: Approximately 18 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 48 months is below that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2025 → Feb 2027 and completion Dec 2025 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2023
First posted
Nov 13, 2023
StartActual
Feb 7, 2023
Primary completionEst.
Feb 2027was Dec 2025
CompletionEst.
Feb 2027was Dec 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Feb 2027
Nov 5, 2026
Study completion
Dec 2025→Feb 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 2025→Feb 2027
    Study completion Dec 2025→Feb 2027
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06127238
Lead sponsor
Beijing Scitech-Mq Pharmaceuticals Limited
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Feb 7, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Jun Guo, Ph D
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Multi-kinase Inhibitor ST-1898

Start the discussion